[go: up one dir, main page]

BR0116762A - Análogos tacrolimus neurotróficos, métodos e uso dos mesmos - Google Patents

Análogos tacrolimus neurotróficos, métodos e uso dos mesmos

Info

Publication number
BR0116762A
BR0116762A BR0116762-6A BR0116762A BR0116762A BR 0116762 A BR0116762 A BR 0116762A BR 0116762 A BR0116762 A BR 0116762A BR 0116762 A BR0116762 A BR 0116762A
Authority
BR
Brazil
Prior art keywords
neurotrophic
tacrolimus
methods
analogues
activity
Prior art date
Application number
BR0116762-6A
Other languages
English (en)
Inventor
Nobuya Matsuoka
Takayuki Yamaji
Bruce Gold
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of BR0116762A publication Critical patent/BR0116762A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"ANáLOGOS TACROLIMUS NEUROTRóFICOS, MéTODOS E USO DOS MESMOS". Os derivados tacrolimus têm altos níveis de atividade neurotrófica e baixos níveis de atividade imunossupressora. Estes compostos são úteis como agentes neurotróficos, particularmente, para prevenir ou tratar ferimento/disfunção neuronal.
BR0116762-6A 2000-12-29 2001-12-31 Análogos tacrolimus neurotróficos, métodos e uso dos mesmos BR0116762A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25850000P 2000-12-29 2000-12-29
PCT/US2001/050419 WO2002053159A1 (en) 2000-12-29 2001-12-31 Neurotrophic tacrolimus analogs

Publications (1)

Publication Number Publication Date
BR0116762A true BR0116762A (pt) 2004-08-10

Family

ID=22980816

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116762-6A BR0116762A (pt) 2000-12-29 2001-12-31 Análogos tacrolimus neurotróficos, métodos e uso dos mesmos

Country Status (18)

Country Link
EP (1) EP1353671A4 (pt)
JP (1) JP2004527472A (pt)
KR (2) KR100794204B1 (pt)
CN (1) CN1293877C (pt)
AR (1) AR035411A1 (pt)
AU (1) AU2002231277B2 (pt)
BR (1) BR0116762A (pt)
CA (1) CA2433384A1 (pt)
CZ (1) CZ20032060A3 (pt)
HU (1) HUP0302521A3 (pt)
IL (1) IL156664A0 (pt)
MX (1) MXPA03005941A (pt)
NO (1) NO20032913D0 (pt)
NZ (1) NZ527209A (pt)
PL (1) PL366301A1 (pt)
RU (1) RU2288716C2 (pt)
WO (1) WO2002053159A1 (pt)
ZA (1) ZA200305806B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
WO2005067928A1 (en) * 2004-01-20 2005-07-28 Astellas Pharma Inc. Method for treating erectile dysfunction
EP1810675A1 (en) * 2006-01-18 2007-07-25 Institut Curie Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421
JP2009102226A (ja) * 2006-02-14 2009-05-14 Meiji Milk Prod Co Ltd 脊髄損傷治療剤
NZ590328A (en) * 2008-07-23 2013-04-26 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat polymyositis and dermatomyositis
US10188695B2 (en) * 2012-02-23 2019-01-29 Sensorion Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US537663A (en) * 1895-04-16 wubstee
JP2799208B2 (ja) * 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5541193A (en) * 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators
GB9202196D0 (en) * 1992-02-01 1992-03-18 Fisons Plc Method of treatment
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use

Also Published As

Publication number Publication date
CA2433384A1 (en) 2002-07-11
AU2002231277B2 (en) 2006-11-30
NZ527209A (en) 2005-09-30
HUP0302521A3 (en) 2007-03-28
EP1353671A4 (en) 2004-07-14
PL366301A1 (en) 2005-01-24
RU2003123493A (ru) 2005-01-20
KR100794204B1 (ko) 2008-01-14
MXPA03005941A (es) 2005-02-14
WO2002053159A1 (en) 2002-07-11
KR20070030331A (ko) 2007-03-15
RU2288716C2 (ru) 2006-12-10
JP2004527472A (ja) 2004-09-09
NO20032913D0 (no) 2003-06-24
EP1353671A1 (en) 2003-10-22
KR20040007431A (ko) 2004-01-24
ZA200305806B (en) 2005-01-26
HUP0302521A2 (hu) 2003-11-28
AR035411A1 (es) 2004-05-26
CN1538843A (zh) 2004-10-20
CN1293877C (zh) 2007-01-10
CZ20032060A3 (cs) 2004-01-14
IL156664A0 (en) 2004-01-04

Similar Documents

Publication Publication Date Title
NO953093D0 (no) Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler
ES2178668T3 (es) Naftilamidas como agentes del sistema nervioso central.
ES2133270T3 (es) Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna.
DE69728585D1 (de) Mittel gegen Juckreiz
EP1140840A4 (en) -G (V) -CARBOXYARYL SUBSTITUTED DIPHENYL UREASINE AS RAF KINASE INHIBITORS
ATE468889T1 (de) Kosmetische zusammensetzung zur behandlung von alternder und/oder gestresster haut
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
TR200400526T4 (tr) Göz kurumasının tedavisi için lipoksin A4 ve analogları
BR0314053A (pt) Pirazolopiridinas e métodos de obtenção e uso das mesmas
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
ES2167544T3 (es) Dioxidos de benzotiazina como antagonistas de la endotelina.
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
SE9604348D0 (sv) Användning av hydroxyguanidiner
BR0015980A (pt) Agente para profilaxia ou tratamento do glaucoma, e, uso de um antagonista de angiotensina ii
BR9908427A (pt) Composições farmacêuticas e uso das mesmas
BR0116762A (pt) Análogos tacrolimus neurotróficos, métodos e uso dos mesmos
EE05124B1 (et) Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP)

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO. LTD.

B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.